These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31844135)

  • 21. Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.
    Bufi E; Belli P; Di Matteo M; Giuliani M; Tumino M; Rinaldi P; Nardone L; Franceschini G; Mulé A; Bonomo L
    Clin Breast Cancer; 2016 Dec; 16(6):e193-e201. PubMed ID: 27431459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
    Watt GP; Sung J; Morris EA; Buys SS; Bradbury AR; Brooks JD; Conant EF; Weinstein SP; Kontos D; Woods M; Colonna SV; Liang X; Stein MA; Pike MC; Bernstein JL
    Breast Cancer Res; 2020 Dec; 22(1):138. PubMed ID: 33287857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
    Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
    Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Background parenchymal enhancement: behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response.
    Teixeira SRC; de Camargo Júnior HSA; Cabello C
    Radiol Bras; 2020; 53(2):95-104. PubMed ID: 32336824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?
    Bermot C; Saint-Martin C; Malhaire C; Sebbag-Sfez D; Mouret-Fourme E; Carton M; Thibault FE
    Eur J Radiol; 2018 Dec; 109():171-177. PubMed ID: 30527300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy.
    Hilal T; Covington M; Kosiorek HE; Zwart C; Ocal IT; Pockaj BA; Northfelt DW; Patel BK
    Breast J; 2018 Nov; 24(6):1010-1014. PubMed ID: 30066421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative analysis of background parenchymal enhancement in whole breast on MRI: Influence of menstrual cycle and comparison with a qualitative analysis.
    Jung Y; Jeong SK; Kang DK; Moon Y; Kim TH
    Eur J Radiol; 2018 Jun; 103():84-89. PubMed ID: 29803391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators.
    Pickles MD; Lowry M; Manton DJ; Turnbull LW
    Eur Radiol; 2015 Apr; 25(4):1097-106. PubMed ID: 25424563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
    Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI Texture Analysis of Background Parenchymal Enhancement of the Breast.
    Amano Y; Woo J; Amano M; Yanagisawa F; Yamamoto H; Tani M
    Biomed Res Int; 2017; 2017():4845909. PubMed ID: 28812015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI in Predicting Breast Cancer Recurrence Risk.
    Arefan D; Zuley ML; Berg WA; Yang L; Sumkin JH; Wu S
    Radiology; 2024 Jan; 310(1):e230269. PubMed ID: 38259203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Background parenchymal enhancement on breast MRI: A comprehensive review.
    Liao GJ; Henze Bancroft LC; Strigel RM; Chitalia RD; Kontos D; Moy L; Partridge SC; Rahbar H
    J Magn Reson Imaging; 2020 Jan; 51(1):43-61. PubMed ID: 31004391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
    Sung JS; Corben AD; Brooks JD; Edelweiss M; Keating DM; Lin C; Morris EA; Patel P; Robson M; Woods M; Bernstein JL; Pike MC
    Breast Cancer Res Treat; 2018 Nov; 172(2):487-496. PubMed ID: 30140962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
    Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
    Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.
    You C; Peng W; Zhi W; He M; Liu G; Xie L; Jiang L; Hu X; Shen X; Gu Y
    Transl Oncol; 2017 Oct; 10(5):786-792. PubMed ID: 28806712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
    Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
    Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk.
    Niell BL; Abdalah M; Stringfield O; Raghunand N; Ataya D; Gillies R; Balagurunathan Y
    AJR Am J Roentgenol; 2021 Jul; 217(1):64-75. PubMed ID: 32876474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.